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Background: Association between DNA alterations and clinical parameters as recurrence, survival or prognosis has
been found in a variety of tumors. A clear association between Medullary Thyroid Carcinoma (MTC) and RET
oncogene mutation has been accepted. Specifically M918T RET mutation represents the main genetic event in
most cases of sporadic MTC (SMTC) and limited chromosomal alterations analyses have been performed.
Methods: In the present work, a comparative genomic hybridization (CGH) study was performed using DNA from a
primary tumor in a M918T RET mutation-positive SMTC patient and from its lymph node metastasis to investigate
additional genetic alterations. We studied a patient with 15 years of follow-up and persistence of disease, confirmed
by periodical elevated serum calcitonin (CT) levels.
Results: Only 3 chromosomal imbalances were identified in the primary tumor, gain of 18p, and loss of 6p and 16p
region, whereas 25 chromosomal imbalances were identified in the metastasis (9 gains and 16 losses).
Conclusion: The chromosomal changes 6p-, 16p-, 18p + could determine in part the oncogenic phenotype in the
primary M918T RET positive tumor and probably related to persistence of high serum CT levels in this patient. The
additional chromosomal changes observed could be related to the metastasis phenotype. We suggest that some
genes mapped at 6p, 16p and 18p chromosomal regions, could act as genes associated to cancer and could be
related to persistent SMTC and good prognosis.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1720753793691097
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Medullary thyroid carcinoma (MTC) is a neuroendo-
crine tumor arising from the parafollicular cells of the
thyroid gland and approximately 75% of cases are spor-
adic type (SMTC) [1]. Survival rate is closely related to
clinical parameters such as tumor stage, age of diagnosis,
elevated postoperative serum calcitonin (CT) levels, and
recurrence of the tumor [2]. Other parameters that* Correspondence: maosal89@yahoo.com
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distribution, and reproduction in any mediumcontribute to survival rates include lymph node metasta-
sis, tumor size >4 cm, extrathyroid and extranodal
tumor extensions [3]. Thus, patients who are treated in
the earlier stages of the disease have a better prognosis.
Patients with tumors that are limited to the thyroid
(stage I) have a survival rate of 95% at 10 and 20 years.
Patients with advanced tumors, stages III and IV, have a
survival rate of 55% and 28% at 10 and 20 years, respect-
ively. Frequently, persistence of the disease is associated
with elevated postoperative serum CT levels and persist-
ence of the tumor increased over time. However, 30% of
SMTC patients continued to show only elevated CTCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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(persistence), even after 15 years [2,3].
At genetic level, the first event in SMTC tumorigenesis
is thought to be the M918T RET mutation (ATG!
ACG) [4-11]. This mutation is associated with 30–66%
of SMTC and 95% of Multiple Endocrine Neoplasia type
2B [4-9]. This mutation has been associated with a poor
prognosis, tumor recurrence and the presence of lymph
node metastases [10-13].
Comparative genomic hybridization (CGH) studies have
been widely applied to cancer research [14,15]. CGH ana-
lysis has been performed in SMTCs showing common
chromosomal alterations as loss in 1p, 3q, 4q, 13q, 17, 22q
and gains in 11q, 12p, 14q, 19q and 22q (Table 1). Some
of these imbalances have been related to specific clinical
behavior such as the clinical outcome [16].
In order to know which chromosomal imbalances occur
in a primary SMTC harboring a M918T RET mutation
and its lymph node metastasis in a patient with 15 years of
clinical follow-up, a CGH analysis was performed.Case presentation
In this study, we report a case of a 70 year-old female
who was diagnosed with SMTC 15 years ago. A total re-
section of the thyroid gland and a resection of the right
lymph nodes in the neck were performed at age 55. At
the time of surgery, a unilateral tumor was detected in
the right lobe of the thyroid. Histopathological findings
confirmed a 7.5x3.5x2cm tumor (T2) with extraglandular
extension, 8/17 positive lymph nodes metastases (N1b)
and no distant metastases (M0) were found. According to
TNM classification, this patient was diagnosed as MTC
stage III. One year later, the patient presented with persist-
ently high serum CT levels (2,400 pg/mL). During a
second surgery, a left lymph nodes resection was per-
formed and histopathological analysis confirmed the
presence of several lymph node metastases (10/49). At
present, the patient is alive and has persistent disease,
confirmed by periodical elevated serum CT levels
(3,193 pg/mL at the latest screening).Table 1 Chromosomal alterations reported in carcinoma tissu
Tissue n Ret mut Gains
SMTC primary tumor 10 Unknown 1q, 6, 7p, 11q, 21q
SMTC primary tumor 9 M918T 1p, 5p, 7q, 8q, 9q, 11q, 16, 19p, 19q, 22
SMTC primary tumor 12 M918T 6p, 6, 7, 12p, 14q, 15q, 16, 19, X
SMTC primary tumor 1 M918T 18p
SMTC metastasis 1 M918T 6 ,14q
SMTC metastasis 1 M918T 2q, 3q, 4p + q, 5p + q, 6q, 8q,
12p + q, 13q, Xq
Note: n: number of cases studied; Ret mut: type of RET mutation; M918T: codon 91
Bold font indicates most common CGH imbalances reported by author.Molecular diagnostic testing confirmed the presence
of the M918T RET mutation in the tumor and lymph
node metastases previously. Interestingly, our case study
demonstrate that despite the mutation and the presence
of several lymph nodes metastases, the patient experi-
enced a good survival rate (15 years after surgery) and
still alive. Then, we focused in search of genetic DNA
alterations by CGH that could be important in the favor-
able prognosis of this patient. The CGH procedure was
performed using reagents and kits from Vysis Inc.
(Downers Grove, IL), following the manufacturer’s
instructions. Tumoral DNA was labeled using the CGH
nick translation kit and the hybridization mixture was
prepared according to the CGH reagent kit, consisting
of 200 ng of spectrum-green labeled tumoral DNA,
200 ng of spectrum-red labeled normal male reference
DNA and 20 μg of human Cot-1 DNA. Hybridization
was performed over 3 days at 37 °C on normal male
metaphase spreads (Vysis, Downers Grove, IL). Digital
images were collected using the Smart Capture (Vysis)
software with a charged coupled device camera mounted
on an epifluorescence microscope. In the primary tumor,
the chromosomal alterations detected were losses in 6p
and 16p and gain in 18p, while 25 chromosomal altera-
tions were detected in the lymph node metastasis with
more losses than gains (Table 1).Discussion
Cancer progression and the metastasis result from the
accumulation of multiple genetic changes. In the current
study, DNA from a primary tumor and a lymph node
metastasis of a persistent SMTC patient, harboring the
M918T RET mutation, was subjected to CGH analysis
to evaluate additional genetic changes. This analysis
demonstrated differences in genetic changes between the
primary tumor and the metastasis, 3 genetic changes vs.
25 genetic changes, respectively. Interestingly, DNA
losses were more common than gains, and a complete
deletion of chromosomes 16, 17, 19, and 20 were
observed in the metastasis (Figure 1). In contrast, a highes from SMTC using CGH analysis
Losses Reference
1p, 3q, 3, 13, 18p, 18q, 22 Hemmer et al., 1999 [18]
q 1p, 2q, 3q, 3, 4q, 9p + q, 10, 12p, 12q, 13q. Frisk et al., 2001 [16]
1p, 3q, 3, 4q, 5q, 9, 11, 13q, 16p,16,
17p, 17, 19, 20q, 20, 22q, X
Marsh et al., 2003 [19]
6p , 16p Present case
X Marsh et al., 2003 [19]
1p, 1q, 6p, 8p, 8q, 9q, 10p, 10q, 11q,
12q, 15q, 16, 17, 19, 20, and 22q
Present case
8 (Met–> Thr). In bold letter the most common CGH gains and losses.
Figure 1 CGH analysis profile from SMTC tissues: A) Primary tumor, B) Metastasis. Red lines to the left of chromosomes represent losses
(CGH fluorescence ratios <0.80), green lines to the right of chromosomes represent gains (ratio >1.20). Abbreviations: LR-T: Primary tumor,
LR-M: Metastasis.
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tastasis have been previously found [16]. These findings
could indicate a complex pattern of DNA alterations
related to metastasis in this patient. It is important to
note that the chromosomal alterations observed in the
primary tumor are also present in its metastasis, indicat-
ing that those changes could be associated to clonal ori-
gin. This is also supported by the presence of the
M918T RET mutation in the metastasis.
To date, only few studies have analyzed chromosomal
imbalances in primary tissue of SMTC [16-18]. Our data
support previous results indicating that the SMTC could
be characterized by more DNA losses than gains [16,18].
One report had suggested that the SMTC harboring the
M918T RET mutation have a higher degree of chromo-
somal instability and usually display a higher number of
DNA alterations [16]. However, the fewer number of
DNA alterations present in the primary tumor of our pa-
tient could be related to persistence or good prognosis.
If this is true, the low number of specific DNA altera-
tions in the primary tumor could be of prognostic value
in SMTC patients.
In other study, the loss of chromosomes 1p, 3q 13q
and 22q were detected in some SMTC patients with
M918T RET mutation. However, the chromosomal
alterations in the metastasis described in the present
study, are partially similar than those described for the
primary tumor in other reports (Table 1). Therefore, it is
possible that some of these DNA alterations could be
associated with clinical parameters such as prognosis,
tumor size, and metastasis. For instance, gains of
chromosome 19 and chromosome 11q12 were observed
in patients whom died of the disease, and they alsoharbored the M918T mutation [16]. It is clear that het-
erogeneity in chromosomal alterations is present in
SMTCs. Several authors have suggested that these CGH
imbalances could contribute to outcome or prognosis
and that those genetic regions may contain genes asso-
ciated to the development of SMTC [16-19]. An overex-
pression of genes involved in proliferation and invasion
such as PTN (7q33); ESM1 (5q11), and CEACAM
(19q13) could also characterize an aggressive SMTC
[20]. Thus, our results are supported by these previous
findings indicating that chromosomal changes at 6p, 16p
and 18p observed in the SMTC, could not be associated
with an aggressive prognosis. On the other hand, it is
widely known that the M918T RET mutation is asso-
ciated with poor prognosis and persistence of the disease
[9-12]. According to our results, the patient harboring
the M918T RET mutation failed in the poor prognosis,
however, she had persistence SMTC. In this case we
hypothesized that our patient harboring the RET muta-
tion (aggressive mutation) could be subjected to an epi-
genetic mechanism as methylation (for instance, an
imprinted mutated allele) allowing the long survival
(good prognosis). Based on our results, we suggest that:
6p, 16p, and 18p regions could contain genes associated
to cancer that are common in human cancer genome
[21,22] and the loss or gain could be associated to good
prognosis and long-term survival. More detailed analyses
are needed to support the existence of good prognostic
markers in chromosomal regions that contain imbal-
ances. To avoid a limited significance about genetic
alterations in persistence SMTC harboring M918T RET
mutation patients should be necessary to analyze more
of these kind of patients.
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In summary, the chromosomal alterations in SMTC are
quite heterogeneous; however, the number and specific
DNA alterations could mark our patient’s prognosis even
when harbors the M918T RET mutation. Losses in 6p
and 16p, and gain in 18p could be related to a favorable
prognostic outcome, persist disease and high serum CT
levels in SMTC.
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